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Background: Myelomatous pleural effusion (MPE) is rare in myeloma patients. We present a consecutive series of patients with 
MPE in a single institution.
Methods: We retrospectively reviewed the medical records of 19 patients diagnosed with MPE between 1989 and 2008 at the Asan 
Medical Center. Diagnoses were confirmed by cytologic identification of malignant plasma cells in the pleural fluid. 
Results: Our patients showed dominance of IgA (36.8%) and IgD (31.6%) subtypes. Of 734 myeloma patients, the incidence of MPE 
was remarkably high for the IgD myeloma subtype (16.7%), compared to the other subtypes (1.4% for IgG and 4.6% for IgA). At the 
time of diagnosis of MPE, elevated serum β2-microglobulin, anemia, elevated serum lactate dehydrogenase, and elevated creati-
nine levels were found in 100%, 89.5%, 83.3%, and 57.9% of the patients, respectively. Approximately one-third (31.3%) of the pa-
tients had adenosine deaminase (ADA) activities in their pleural fluid exceeding the upper limit of the reported cutoff values for tu-
berculous pleural effusion (55.8 U/L). Chromosome 13 abnormality was seen in 77.8% of the tested patients. The median survival 
period from the development of MPE was 2.8 months.
Conclusions: Patients with MPE have aggressive clinical and laboratory characteristics. The preponderance of IgD myeloma in MPE 
patients is a noteworthy finding because IgD myeloma is a rare subtype. Elevated ADA activity in the pleural fluid is also notewor-
thy, and may be helpful for detecting MPE. Physicians treating myeloma patients should monitor the development of MPE and con-
sider the possibility of a worse clinical course.
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INTRODUCTION
Pleural effusion is a relatively uncommon finding in my-
eloma patients, with a frequency of only 6%, and is usually 
associated with benign conditions such as nephrotic syn-
drome, pulmonary embolism, congestive heart failure sec-
ondary to amyloidosis, and infection [1, 2]. Myelomatous 
pleural effusion (MPE) is rare, occurring in less than 1% of 
cases [1]. To date, the majority of studies in the literature have 
reported experiences with a single case of MPE and provide 
a brief literature review [3-5]. To the best of our knowledge, 
there has been only one case series of MPE in the English 
language literature [6]. In this report, the authors concluded 
that MPE in patients with myeloma is often associated with 
high-risk disease, including deletion 13 chromosomal ab-
normality and indicated a poor prognosis despite aggressive 
local and systemic treatment. Here, we report a further case 
series of 19 patients who were diagnosed with MPE at a sin-
gle institution in Korea.
MATERIALS AND METHODS
We retrospectively collected data on patients who were 
diagnosed with multiple myeloma with pleural effusion from 
October 1989 to December 2008 at the Asan Medical Cen-
ter. We reviewed medical records for 734 patients with mul-
tiple myeloma, and found that 54 of these cases were diag-226     www.kjlm.org
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nosed with pleural effusion. Of these 54 eligible cases, 12 
were excluded because of insufficient medical records or 
lack of pleural fluid analysis data. Among the remaining 42 
patients, 19 were diagnosed with MPE and 23 had benign 
pleural effusion. 
Diagnosis of multiple myeloma was based on the criteria 
of the International Myeloma Working Group [7]. The MPE 
diagnosis was established by cytologic identification of ma-
lignant plasma cells in the pleural fluid (Fig. 1). The data 
collected from the patients’ medical records included the 
characteristics of pleural effusion, paraprotein isotype, and 
various laboratory parameters at the onset of pleural effu-
sion. Early-onset effusion was defined as effusion occurring 
at the time of the initial diagnosis of myeloma or during the 
first cycle of chemotherapy. Clinical staging for myeloma 
patients was performed according to the International Stag-
ing System (ISS), which is the most widely used method for 
assessing the prognosis of myeloma [8]. A study on Japa-
nese patients with IgD myeloma proposed a new staging 
system based on the light chain subtype and white blood 
cell (WBC) count [9]. They designated patients with a WBC 
count of 7.0×10
9 cells/L or more and a λ subtype as the high-
risk group, while patients with a WBC count less than 7.0× 
10
9 cells/L and a κ subtype were classified into the low-risk 
group. Those with an intermediate status were classified into 
the middle-risk group. In our study, patients with IgD my-
eloma were separately staged using this new staging system. 
Laboratory parameters were reviewed, including serum cal-
cium, serum creatinine, hemoglobin, serum M-protein, se-
rum β2-microglobulin, serum lactate dehydrogenase (LD), 
serum C-reactive protein (CRP), and adenosine deaminase 
(ADA) activity in the pleural fluid. Chromosome analysis 
was conducted using bone marrow samples at the time of 
diagnosis. Survival was calculated from the onset of MPE to 
death. Continuous data are presented as medians (ranges) 
according to their non-parametric distribution. The institu-
tional review board of Asan Medical Center approved this 
study. 
RESULTS
Among the 734 patients with multiple myeloma seen at 
our institution from October 1989 through December 2008, 
19 (2.6%) had MPE. The clinical characteristics and out-
comes of MPE in these patients are described in Table 1. Of 
the 19 patients with MPE, 13 were men and 6 were women. 
The median age of these patients was 58 yr (range: 21-77 yr). 
Two cases of extraosseous plasmacytoma were diagnosed, 
one in the paranasal sinus and one in the mediastinum, with-
out evidence of plasmacytosis in the bone marrow. The most 
common myeloma isotype was IgA (36.8%, 7/19), followed 
by IgD (31.6%, 6/19), IgG (26.3%, 5/19), and light chain (5.3%, 
1/19). Considering that the overall frequency of IgD myelo  ma 
was 4.9% in our institution, the frequency of this subtype in 
the MPE patients (31.6%) was unexpectedly high (Table 2). 
Furthermore, there was an exceptionally high incidence of 
MPE in patients with IgD myeloma (16.7%, 6/36) compared 
to those with IgG (1.4%, 5/362), IgA (4.7%, 7/150), or the 
light chain subtype (0.6%, 1/167) (Table 2). The frequencies 
of early-onset effusion, bilateral location, and parapneumo-
nic effusion were 42.1%, 68.4%, and 15.8%, respectively. Os-
teolytic bone lesions and extramedullary involvement other 
than in the pleural space were observed in 68.4% and 29.4% 
of patients, respectively. At diagnosis, 73.3% (11/15) of pa-
tients belonged to ISS stage III. According to the new stag-
ing system for IgD myeloma [9], the majority of our IgD 
myeloma patients (66.7%, 4/6) were classified into the mid-
dle-risk group, while 33.3% (2/6) were classified into the high-
risk group. None were classified into the low-risk group. Over-
all, the prognosis was poor, with an overall mortality of 57.9%. 
The median survival time from the development of pleural 
effusion was 2.8 months (range: 0.2-15.6 months) (Table 1). 
Laboratory evidence of advanced disease, such as elevated 
serum β2-microglobulin (>2.0 mg/L), anemia (hemoglo-
bin <13 g/dL in males or <12 g/dL in females), elevated 
serum LD (>250 IU/L), elevated serum creatinine (>1.7 
mg/dL), elevated serum CRP (>2.0 mg/L), and hypercalce-
mia (>10.5 mg/L), was seen in 100% (11/11), 89.5% (17/19), 
83.3% (10/12), 57.9% (11/19), 42.9% (6/14), and 16.7% (3/18) 
of patients, respectively. The median level of serum M-pro-
Fig. 1. Malignant plasma cells in the pleural effusion (case M). The cells have 
large, eccentrically placed and pleomorphic nuclei and prominent nucleoli 
(Wright-Giemsa stain, ×1,000).
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tein was 2.53 g/dL (range: 0.0-8.30 g/dL), and the median 
ADA activity in the pleural fluid was 37.1 U/L (range: 2.8-
117.8 U/L). The cutoff value of ADA activity to exclude tu-
berculous pleural effusion has been reported to range from 
38 to 55.8 U/L [10-12]. In our study, approximately one-third 
of MPE patients (31.3%, 5/16) had ADA activities exceed-
ing the upper limit of the reported cutoff values (55.8 U/L). 
However, we could not find any evidence of active pulmo-
nary tuberculosis in the medical records of our patients. 
Bence-Jones proteinuria was present in 82.4% (14/17) of 
patients. Bone marrow cytogenetic analysis was conducted 
for 10 patients, including one (case S) who had extraosse-
ous plasmacytoma and a normal karyotype in the marrow 
sample. The frequency of chromosome 13 abnormality (mo-
nosomy 13 or deletion of 13q) was 77.8% (7/9) of tested pa-
tients, excluding case S. These laboratory findings are sum-
marized in Table 3. 
DISCUSSION
The most noteworthy finding in this case series was the 
high frequency of IgD myeloma among MPE patients. Gen-
erally, the most common isotype in myeloma is IgG (50%), 
followed by IgA (20%), light chain (20%), and IgD, IgE, IgM, 
and biclonal (<10%) [13]. The distribution of immunoglo-
bulin isotypes in our myeloma patients was consistent with 
this general description (Table 2). Despite this, we found 
that the frequencies of IgA and IgD subtypes in our MPE 
patients were quite high (36.8% and 31.6%, respectively). 
This predominance of IgA is consistent with previously re-
ported findings of 3 separate studies, which found IgA my-
eloma in 80%, 27.6%, and 36.4% of MPE patients [3, 4, 6]. 
In contrast, the high frequency of IgD myeloma in our MPE 
patients was exceptional because IgD myeloma has account  ed 
Table 1. Clinical characteristics and outcomes of 19 patients with MPE
ID Age (yr) Gender Ig class Onset Location Parapneumonic 
effusion
Extramedullary 
involvement
Osteolytic  
lesions ISS stage New risk 
  grouping*
Clinical  
outcome
Post-MPE survival 
(months)
A 59 F Gλ Late Bilateral No No Yes ND - Death 1.3
B 62 M Aκ Late Bilateral Yes No Yes III - F/U loss 9.7
C 73 M Aλ Late Bilateral Yes No Yes III - Death 1.0
D 63 M Aλ Late Bilateral No No Yes II - F/U loss 2.7
E 75 M Aκ Early Bilateral No No No III - F/U loss 0.2
F 53 M Dλ Late Left No Yes Yes III Middle Death 3.7
G 39 M Dλ Early Right No Yes Yes ND High Death 3.7
H 53 F Aκ Late Left No -
† No -
‡ - F/U loss 0.7
I 77 M Aλ Late Bilateral No Yes Yes III - F/U loss 6.7
J 49 F Dλ Late Bilateral No Yes Yes III Middle Death 0.4
K 58 M Gλ Late Bilateral No No Yes III - Death 1.1
L 64 F λ Early Left Yes No No III - Death 3.0
M 53 M Gκ Late Bilateral No No Yes II - Death 0.8
N 47 M Aκ Early Left No No Yes II - F/U loss 1.9
O 67 M Dλ Early Bilateral No No Yes III Middle F/U loss 15.6
P 21 F Dκ Late Bilateral No No No III Middle Death 15.3
Q 59 M Dλ Early Bilateral No No No III High F/U loss 0.3
R 52 M Gλ Early Right No Yes Yes II - Death 2.8
S 48 F Gκ Early Bilateral No -
† No -
‡ - Death 4.1
*Grouping of IgD myeloma was based on reference 9; 
†Two patients with extraosseous plasmacytoma were excluded from the analysis; 
‡Two patients with extraosseous plasmacy-
toma were excluded from estimation of clinical stage.
Abbreviations: ID, identification; ISS, International Staging System; MPE, myelomatous pleural effusion; F, female; M, male; ND, not described; F/U, follow up.
Table 2. Comparison of the frequency of immunoglobulin isotypes between 
myeloma patients and MPE patients in our institution
Immunoglobulin  
isotype
Patients with multiple myeloma
(N=734)
Patients with MPE
(N=19)
IgG 362 (49.3%) 5 (26.3%)
IgA 150 (20.4%) 7 (36.8%)
Light chain 167 (22.8%) 1 (5.3%)
IgD 36 (4.9%) 6 (31.6%)
Others* 19 (2.6%) -
*Others included biclonal gammopathy, IgM subtype, or non-secretory type.
Abbreviation: MPE, myelomatous pleural effusion.228     www.kjlm.org
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for only 0.7-5.7% of myeloma cases in prior studies [14], and 
the frequency of IgD myeloma in our institution was 4.9%. 
IgD myeloma is different from IgG and IgA myeloma, and 
one of the distinct characteristics of IgD myeloma is a fre-
quent occurrence of extraosseous spread [14, 15]. Reflect-
ing this characteristic, there have been 7 case reports of IgD 
myeloma with MPE in the English literature [16-22]. Ac-
cording to these reports, the predominance of IgD myeloma 
in MPE is thought to result from a tendency for extraosse-
ous spread of IgD myeloma. 
Another noteworthy finding was the presence of high 
ADA activity in the pleural fluid of some of the MPE pa-
tients. High ADA activity in pleural fluid strongly favors tu-
berculous pleural effusion. Even though we did not find any 
evidence of active pulmonary tuberculosis in our patients, 
approximately one-third of patients showed ADA activities 
exceeding the upper limit of the reported cutoff value for 
tuberculous pleural effusion. ADA is present in virtually all 
human tissues, but the highest levels are found in lymphoid 
tissues, such as the lymph nodes, spleen, and thymus [23]. 
In previous studies investigating the levels of ADA in hema-
tologic malignancies, abnormal activities were found in some 
myeloma cases [24, 25]. High ADA levels in the pleural fluid 
have been previously reported in 2 patients with MPE: 61 
U/L in a patient with IgA myeloma, and 50.2 U/L in a pa-
tient with IgD myeloma [3, 21]. Thus, we could assume that 
a small fraction of myeloma cells express ADA on their sur-
faces, and this may partly explain the high ADA levels in 
some MPE patients. However, considering that ADA plays 
a central role in the differentiation and maturation of the 
lymphoid system, elevated ADA in MPE patients might in-
dicate changes in immunological activity following antigenic 
Table 3. Laboratory characteristics of 19 patients with MPE
ID Calcium  
(mg/dL)
Creatinine 
(mg/dL)
Hemoglobin 
(g/dL)
M-protein  
(g/dL)
Bence-Jones 
proteinuria
β2-microglobulin 
(mg/L) LD (IU/L) CRP (mg/dL) ADA (U/L) Monosomy 13  
or del(13q)
A 7.1 0.7 11.0 4.94 Yes NA 8,699 NA NA NA
B 8.2 0.7 8.2 NA NA NA NA   1.2 43.4 NA
C 9.3 1.4 8.9 NA NA   8.0 818   1.1 14.2 No*
D 7.8 6.3 8.4 4.10 Yes   7.3 307   5.9 10.2 NA
E 12.0 2.4 8.4 8.30 Yes 23.6 NA NA 15.7 NA
F 7.2 4.2 8.4 NA Yes NA NA 14.3 68.4 Yes
†
G 5.9 8.8 8.6 2.20 Yes NA NA NA NA NA
H 8.7 2.3 8.3 NA No NA 1,342 23.4 84.2 NA
I 7.7 3.3 8.4 NA Yes NA 1,241 NA   2.8 NA
J 9.2 0.9 9.9 0.81 No NA NA 2.0 NA Yes
‡
K NA 8.2 10.0 4.37 Yes 42.5 NA 16.3 43.3 NA
L 7.9 3.4 11.3 0.00 Yes 10.6 849   0.3 30.1 NA
M 7.4 2.7 5.5 3.70 Yes 19.7 326   8.2 108.5 Yes
§
N 11.7 1.8 9.8 4.78 Yes   7.7 NA   3.6 41.7 Yes
II
O 8.2 1.0 8.7 0.99 Yes 13.0 137 NA 117.8 Yes
¶
P 8.0 0.9 7.0 0.57 Yes NA 265   1.0   32.5 No**
Q 11.4 4.6 10.0 0.69 Yes 29.8 279   0.7   30.7 Yes
††
R 8.7 1.1 13.2 2.86 Yes   2.7 221   0.5   22.9 Yes
‡‡
S 8.5 1.2 14.0 1.90 No   3.1 266   2.0   60.6 No
§§
*Despite that bone marrow cytogenetics was conducted, a full description of the karyotype was not found in the medical record of this patient. However, we identified the summa-
rized description, which was “hypertriploidy and very complex abnormality involving chromosomes 1, 3, 17, and 21”; 
†Karyotype was 44,XY,+1,der(1;16)(q10;p10),del(5)(p13),del 
(5)(q13),-10,-11,-13,-14,-17,der(19)t(17;19)(q21;p13.3),+der(?)t(11;?),+mar[5]/46,XY[2]; 
‡Karyotype was 42,X,-X,+der(1;16)(q10;p10),dic(1;6)(p11;p25),-5,-6,-10,-13,der(14)
t(6;14)(p21;q32)[6]/42,idem,del(3)(p21),del(4)(q33)[7]/47,X,X,+1,der(1;16)(q10;p10),dic (1;6)(p11;p25),t(6;14)(p21;q32),13,+der(14)t(6;14),+15,+21[4]/47,X,X,+1,der(1;16)
(q10;p10),dic(1;6)(p11;p25),del(5)(q31),t(6;14)(p21;q32),-13,+der(14)t(6;14),+15,add(18) (q21),+21[3]; 
§Karyotype was 45,XY,+add(1)(p13),-2,del(6)(q15),-13[1]/46,XY[20]; 
IIKaryotype was 72,XX,-Y,-1,+7,+12,-13,+14,+15,-17,-17,der(19)t(1;19)(q11;p13.3),-20,-20,-22,-22,+der(?)t(1;?)(q21;?),+7mar[19]/46,XY[1]; 
¶Karyotype was 46,XY,add(7)
(q11.2),del(13)(q12q14),add(14)(q32),del(14)(q24)[13]/46,XY[3]; **Karyotype was 46,XX[30]; 
††Karyotype was 46,XY,add(1)(q21),+7,-13,del(14)(q32),+21,-22[4]/46,idem,add 
(16)(q22)[20]/46,XY[1]; 
‡‡Karyotype was 47,XY,der(1)t(1;1)(p36.3;q11),der(1)t(1;14)(q44;q11),add(3)(q27),+7,+12,-13,-15,+21[3]/46,XY[27]; 
§§This patient had extraosseous 
plasmacytoma. Bone marrow cytogenetics revealed a normal female karyotype (46,XX[20]).
Abbreviations: MPE, myelomatous pleural effusion; ID, identification; LD, serum lactate dehydrogenase level; CRP, serum C-reactive protein; ADA, adenosine deaminase activity in 
pleural fluid; NA, not available.Cho Y-U, et al.  •  Myelomatous Pleural Effusion
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challenges, regardless of the ADA expression on myeloma 
cells. 
The reported median survival time after the development 
of MPE is less than 4 months [4-6], consistent with the me-
dian survival time of our patients. The reason that MPE pa-
tients showed short survival times is clear. At diagnosis, the 
majority of patients were classified into advanced clinical 
stages using either the ISS system or the new risk grouping 
in the case of IgD subtype. At the time of development of 
MPE, the laboratory characteristics of many patients indi-
cated an aggressive clinical course. In addition, MPE repre-
sents clinical progression of the disease in itself. In terms of 
prognosis, it was interesting that chromosome 13 abnor-
mality was found with high frequency in our MPE patients, 
despite the relatively small number of patients tested. Chro-
mosome 13 abnormality has been observed in 14-19% of 
myeloma patients using conventional cytogenetics [26, 27]. 
While fluorescence in situ hybridization is 2- to 3-fold more 
sensitive than metaphase cytogenetics for detecting such 
abnormalities, the karyotypes of our case series were based 
on conventional cytogenetic techniques. Therefore, the fre-
quency of chromosome 13 abnormalities observed in our 
MPE patients (77.8%) was exceptionally high. However, 
this is very similar to the incidence (81.8%, 9/11) in MPE 
patients reported in a previous case series [6]. Since chro-
mosome 13 abnormality has been associated with adverse 
clinical outcomes in myeloma patients [6, 26, 27], this may 
explain, at least in part, the association between MPE and a 
poor prognosis.
This study has two limitations. First, the study population 
was small. Although we described a few distinctive features 
of MPE patients, we cannot completely exclude possible bias 
caused by the small number of patients. Second, the diag-
noses of MPE were made by cytological examination. Other 
ways of confirming the myelomatous etiology are the dem-
onstration of monoclonal protein on pleural fluid electro-
phoresis, and histologic confirmation using a pleural biopsy 
specimen. Since hemorrhagic effusions are common, pro-
tein electrophoresis of the pleural fluid is an unreliable me-
thod for documenting myelomatous pleural involvement 
[6]. Pleural biopsy also has a low diagnostic yield for plasma 
cell infiltrates. Because of the patchy involvement of the ple-
ura by the tumor, it may be difficult to diagnose myeloma-
tous infiltration using a blind, closed pleural biopsy [4]. For 
these reasons, the best means of diagnosis is probably cyto-
logic identification of malignant plasma cells within the ple-
ural fluid [4]. However, it is possible that a microscopist could 
fail to identify the malignant plasma cells, particularly if they 
are few in number or in vitro degeneration has occurred. 
Despite these limitations, this case series describing a popu-
lation of MPE patients, rather than a single case report or a 
review of the reported cases in the literature, represents a 
significant contribution, since it is only the second study of 
its kind.
In conclusion, our study found that MPE is highly associ-
ated with a predominance of IgA and IgD subtypes, and with 
aggressive clinical and laboratory characteristics. In particu-
lar, the preponderance of IgD myeloma in our MPE patients 
was an unexpected finding. Although the incidence of MPE 
was exceptionally high in IgD myeloma patients compared 
to the other subtypes, further studies are needed to deter-
mine whether IgD myeloma is strongly associated with the 
development of MPE. Elevated ADA activity in the pleural 
fluid can be useful for screening MPE. The high incidence 
of chromosome 13 abnormality in MPE patients is also sig-
nificant, since the detection of these abnormalities is a criti-
cal prognostic factor for myeloma. Physicians who treat my-
eloma patients should monitor closely for the development 
of MPE and consider the possibility that their clinical course 
will deteriorate.
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